Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

LACHEN, Switzerland, July 4, 2022 /PRNewswire/ --

• Octapharma to present new clinical and scientific data from across Octapharma's haematology and critical care portfolios during the ISTH 2022 Congress
• Data to be presented in 11 poster presentations and during two Supported Symposia
• New data from the extensive clinical trial programme with Nuwiq (simoctocog alfa) to be presented, confirming Nuwiq's efficacy and safety profile

The latest developments in Octapharma's haematology and critical care portfolios will be presented at the 30^th International Society on Thrombosis and Haemostasis (ISTH) Congress on July 9–13, 2022, in London, UK. The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting. Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.

Poster presentations at the Congress will include data from the Nuwiq clinical trial programme, including a pooled analysis of long-term data from clinical trials and the first presentation of the results of the global GENA-99 study of Nuwiq in real-world clinical practice. These studies confirm the proven efficacy and safety profile of Nuwiq in patients with haemophilia A. The safety and immunogenicity results from the phase I/II study of OCTA101, a recombinant FVIII developed for subcutaneous administration, will also be presented, following the recent decision to terminate the study due to safety concerns. Updates from the clinical development programme with the four-factor prothrombin complex concentrate Octaplex and the high-purity, double virus inactivated, lyophilized human antithrombin III concentrate Atenativ will also be provided, demonstrating Octapharma's commitment to clinical research and development in critical care.

The following posters will be presented.

Monday July 11, 18:30–19:30

• PB0690. Dose optimisation in children with severe haemophilia A on long-term octanate prophylaxis. Presenting Author: Evgeny Dmitriev
• PB0672. Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
• PB0559. LEX-210: a phase 3, randomized, double-blinded study of four-factor prothrombin complex concentrate in patients with acute major bleeding on direct oral anticoagulant therapy with factor Xa inhibitors. Presenting Author: Ravi Sarode
• PB0560. Use of heparin-calibrated assays to estimate anti-factor Xa activity of factor Xa inhibitors (FXaI): a literature correlation analysis. Presenting Author: Ravi Sarode
• PB0716. Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency During Surgery or Childbirth. Presenting Author: Cristina Solomon
• PB0541. Freeze-dried plasma development and assessment of biochemical quality. Presenting Author: Andrea Heger
• VPB0492. LEX-211 (FARES-II): a phase 3, prospective, active-control randomised study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients. Presenting Author: Jeannie Callum

Tuesday July 12, 18:30–19:30